Back to Search
FUAD SHIHAB, MD
MD
Nephrology Physician
NPI: 1700976321IndividualAccepts Medicare
Specialties, Licenses & Credentials
Nephrology PhysicianPrimary
Internal Medicine — Nephrology
Code: 207RN0300X
187970-1205(UT)
Education
OTHER
Class of 1985
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
PMID 15740555·Clin Transplant·2005
3-trial
Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium.
PMID 16008604·Clin Transplant·2005
3-trial
Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
PMID 11294511·Ther Drug Monit·2001
4-observational
Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation.
PMID 19202436·Transplantation·2009
7-preclinical
Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
PMID 18475181·Transplantation·2008
4-observational
Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.
PMID 16926534·Am J Nephrol·2006
7-preclinical
Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity.
PMID 15729167·Transplantation·2005
7-preclinical
Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
PMID 15086465·Kidney Int·2004
7-preclinical
Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.
PMID 15021829·Transplantation·2004
7-preclinical
Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.
PMID 14629285·Am J Transplant·2003
7-preclinical
Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity.
PMID 12631117·Kidney Int·2003
7-preclinical
Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity.
PMID 12110003·Kidney Int·2002
7-preclinical
Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.
PMID 12099512·Am J Transplant·2002
7-preclinical
Renin-angiotensin system in chronic renal allograft dysfunction.
PMID 11705287·Contrib Nephrol·2001
6-review
Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity.
PMID 11468554·Transplantation·2001
7-preclinical
Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.
PMID 10972680·Kidney Int·2000
7-preclinical
No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study.
PMID 19307792·Transplantation·2009
2-rct
RIFLE criteria accurately identifies renal dysfunction and renal failure in elderly patients with upper gastrointestinal hemorrhage: a pilot study.
PMID 19434015·South Med J·2009
8-other
A population-based assessment of the familial component of acute kidney allograft rejection.
PMID 19286691·Nephrol Dial Transplant·2009
4-observational
Successful treatment of recurrent Henoch-Schönlein purpura in a renal allograft with plasmapheresis.
PMID 17973963·Am J Transplant·2008
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 50 N MEDICAL DR
SALT LAKE CITY, UT 84132 - Phone
- (801) 581-6709
Quick Facts
- NPI
- 1700976321
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile